Research programme: autologous gene therapy - Orchard Therapeutics

Drug Profile

Research programme: autologous gene therapy - Orchard Therapeutics

Alternative Names: Ex-vivo lentiviral gene therapy - Orchard Therapeutics; OTL 201; OTL 202

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Central Manchester University Hospitals NHS Foundation Trust; University of Manchester
  • Developer Orchard Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; N-sulfoglucosamine-sulfohydrolase-expression-stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Metabolic disorders; Mucopolysaccharidosis III
  • No development reported Immunological disorders

Most Recent Events

  • 28 May 2018 No recent reports of development identified for preclinical development in Immunological-disorders in United Kingdom (Parenteral)
  • 27 Nov 2017 Orchard acquires license to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B from Manchester University
  • 27 Nov 2017 Pharmacodynamics data from a preclinical trial Mucopolysaccharidosis III typeB released by Orchard
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top